Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Regulatory News (EVG)

  • There is currently no data for EVG

Statement re Offer Approaches

12 Sep 2011 11:36

RNS Number : 0512O
Evolution Group PLC
12 September 2011
 



The Evolution Group PLC

12 September 2011

The Evolution Group plc ("Evolution")

Statement regarding Offer Approaches

On 16 August 2011, The Evolution Group Plc ("Evolution") announced, amongst other things, that the Board had received approaches from a number of parties, in addition to the approach from Investec plc ("Investec"), who were interested in either part or the whole of the Company.

On 8 September 2011, Canaccord Financial Inc. announced that it will not proceed with an offer and will be bound by Rule 2.8 of the City Code on Takeover and Mergers (the "Code").

On 9 September 2011, Investec announced a recommended share offer for Evolution under Rule 2.5 of the Code. The Board of Evolution confirms that discussions with all parties other than Investec have now ceased.

 

-END-

 

Enquiries:

The Evolution Group Plc Tel: 020 7071 4300

Alex Snow, CEO, The Evolution Group PLC

 

Pelham Bell Pottinger Tel: 020 7861 3925

Victoria Geoghegan

 

The directors of Evolution accept responsibility for the information contained in this announcement. To the best of the knowledge and belief of the directors (who have taken all reasonable care to ensure that such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
OFDGGURPBUPGGUP
Date   Source Headline
28th Mar 20197:00 amRNSPoster presentation of Imperial College data
25th Mar 20197:00 amRNSSFX-01 meets primary endpoints in STEM trial
18th Mar 20192:01 pmRNSPrice Monitoring Extension
18th Mar 20197:00 amRNSUpdate on SFX-01 trial read-out dates
5th Mar 20197:00 amRNSSFX-01 data published in peer reviewed journal
6th Feb 20193:30 pmRNSHolding(s) in Company
5th Feb 20197:00 amRNSClinical trial update confirms read-outs on track
30th Jan 20195:28 pmRNSGrant of Options
23rd Jan 20197:00 amRNSSFX-01 featured in Nature Reviews Drug Discovery
22nd Jan 20197:00 amRNSChange of Adviser
19th Dec 20186:02 pmRNSShare option exercise and issue of equity
12th Dec 20187:00 amRNSInterim Results
10th Dec 20183:00 pmRNSNominated Adviser Status
4th Dec 20187:00 amRNSPoster Presentation of SFX-01 and Trial Update
3rd Dec 20187:00 amRNSNotification of Half Year Results
19th Nov 20187:00 amRNSInvestor Presentation in Manchester
8th Nov 20187:00 amRNSDirectorate Changes
23rd Oct 20189:57 amRNSHolding(s) in Company
18th Oct 20187:00 amRNSPlacing
18th Sep 20187:00 amRNSInvestor Symposium
11th Sep 20187:00 amRNSNotice of Investor Symposium
26th Jul 20183:22 pmRNSResult of AGM
26th Jul 20187:00 amRNSAGM Statement
25th Jul 20187:00 amRNSFinal Patient Recruited in STEM Phase IIa Trial
10th Jul 201811:00 amRNSGrant of share options, issue of equity and TVR
29th Jun 201810:45 amEQSHardman & Co Research: Evgen Pharma (EVG): 2018, a pivotal year
21st Jun 201812:30 pmRNSPosting of Annual Report and AGM Notice
13th Jun 20182:15 pmEQSHardman & Co Research: Evgen Pharma (EVG): Encouraging interim data from the STEM trial
13th Jun 20187:00 amRNSFull Year Results
11th Jun 20189:05 amRNSSecond Price Monitoring Extn
11th Jun 20189:00 amRNSPrice Monitoring Extension
11th Jun 20187:00 amRNSInterim Update on STEM Trial
7th Jun 20184:40 pmRNSSecond Price Monitoring Extn
7th Jun 20184:35 pmRNSPrice Monitoring Extension
30th May 20187:00 amRNSNotification of Preliminary Results
15th May 201811:00 amRNSPrice Monitoring Extension
14th May 20187:00 amRNSUpcoming Investor Presentations
2nd May 20187:00 amRNSGrant of further European patent
26th Apr 20184:40 pmRNSSecond Price Monitoring Extn
26th Apr 20184:35 pmRNSPrice Monitoring Extension
24th Apr 20187:00 amRNSPresentation at World Orphan Drug Congress USA
20th Mar 20187:00 amRNSResearch Collaboration with Imperial College
5th Mar 20187:00 amRNSUpdate on Novel Sulforaphane Analogues
15th Jan 20187:00 amRNSPoster Presentation of SFX-01 Mechanistic Data
10th Jan 20184:31 pmRNSNotification of Major Interest in Shares
5th Jan 20189:49 amRNSNotification of Major Interest in Shares
5th Jan 20189:48 amRNSNotification of Major Interest in Shares
2nd Jan 20185:44 pmRNSTotal Voting Rights
28th Dec 201711:49 amRNSResult of General Meeting
22nd Dec 201710:10 amRNSGrant of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.